Specifically, next-generation sequencing has transformed neonatal care significantly, and it also works rapidly. This is because NGS identifies rare genetic disorders, so it then provides clinical clarity. Therefore, the molecular diagnostic yield of exome sequencing (ES) and genome sequencing (GS) is a vital metric. For example, a recent meta-analysis evaluated 48 cohorts, and it established new benchmarks. Overall, both modalities achieved a 39.4% rate, so they are equally effective. Consequently, this study supports using NGS, and also it advocates for early testing. In addition, early testing prevents delays, and thus it improves outcomes because doctors act faster.

Maximizing Molecular Diagnostic Yield with Rapid Sequencing

Furthermore, researchers compared trio-based sequencing and non-trio approaches specifically to evaluate performance. Although results showed a success trend, yet the findings were not statistically significant. However, rapid GS still appeared more effective, and it outperformed rapid ES in several subgroups. Moreover, the meta-regression indicated that success rates stayed consistent, and then they did not change over time. Consequently, clinicians can rely on these technologies, and they can use them anytime. Therefore, the utility remains high, so it is a standard. Additionally, identifying a genetic cause helps, and it refines medical management. For instance, specific diagnoses lead to treatments, and also they reduce trial-and-error. Significantly, this saves time, and furthermore, it assists parents. Overall, integrating genomics is a goal, and consequently, it is recommended. Thus, the value is clear because it offers answers and hope.

Frequently Asked Questions

What is the typical molecular diagnostic yield for GS in neonates?

The meta-analysis found a molecular diagnostic yield of 39.4% for both ES and GS in critically ill infants.

Is trio sequencing better than singleton sequencing?

While trio sequencing often provides clearer results, the meta-analysis found the higher yield was a trend rather than a statistically significant difference.

How does rapid GS compare to standard sequencing?

Rapid GS is designed for acute settings and typically provides results much faster, often trending toward higher diagnostic success in critical care.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Yang J et al. Molecular Diagnostic Yield of Exome Sequencing and Genome Sequencing in Critical Ill Neonates and Infants: A Systematic Review and Meta-Analysis. Genet Med. 2026 Jun 09. doi: undefined. PMID: 42267533.


2. Onorato AC, Gosselin R, Chaudhari BP, Alvarado C, White P, Garg V, Bigelow AM. Diagnostic yield of exome and genome sequencing for critically ill pediatric cardiac patients. Transl Pediatr 2026;15(2):44. doi: 10.21037/tp-2025-1-877.


3. Wojcik MH, Lemire G, Berger E, et al. Genome Sequencing for Diagnosing Rare Diseases. N Engl J Med 2024;390:1985-97.